



## Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain

Guan-Sheng Jiao<sup>a,†</sup>, Seongjin Kim<sup>a,†</sup>, Mahtab Moayeri<sup>b</sup>, Devorah Crown<sup>b</sup>, April Thai<sup>a</sup>, Lynne Cregar-Hernandez<sup>a</sup>, Linda McKasson<sup>a</sup>, Banumathi Sankaran<sup>c</sup>, Axel Lehrer<sup>a</sup>, Teri Wong<sup>a</sup>, Lisa Johns<sup>a</sup>, Stephen A. Margosiak<sup>a</sup>, Stephen H. Leppla<sup>b</sup>, Alan T. Johnson<sup>a,\*</sup>

<sup>a</sup> PanThera Biopharma, LLC, Aiea, HI 96701, USA

<sup>b</sup> Laboratory of Bacterial Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

<sup>c</sup> Advanced Light Source, Lawrence Berkeley Laboratory, Berkeley, CA 94720, USA

### ARTICLE INFO

#### Article history:

Received 10 November 2011

Revised 24 January 2012

Accepted 24 January 2012

Available online 1 February 2012

#### Keywords:

Anthrax

Lethal factor

Inhibitor

In vitro ADME

X-ray crystallography

### ABSTRACT

Four core structures capable of providing sub-nanomolar inhibitors of anthrax lethal factor (LF) were evaluated by comparing the potential for toxicity, physicochemical properties, in vitro ADME profiles, and relative efficacy in a rat lethal toxin (LT) model of LF intoxication. Poor efficacy in the rat LT model exhibited by the phenoxyacetic acid series (**3**) correlated with low rat microsome and plasma stability. Specific molecular interactions contributing to the high affinity of inhibitors with a secondary amine in the C2-side chain were revealed by X-ray crystallography.

© 2012 Elsevier Ltd. All rights reserved.

Anthrax lethal factor (LF) and edema factor (EF) are two proteins secreted by the Gram-positive bacterium *Bacillus anthracis* to assist in the infection of the host.<sup>1</sup> LF is a zinc metalloproteinase that disrupts cell signaling pathways by direct cleavage of MEK proteins,<sup>2</sup> while EF is a Ca<sup>2+</sup>/calmodulin-dependant adenylate cyclase that increases cytosolic cAMP and also interferes with cell signaling.<sup>3</sup> When combined with a third protein protective antigen (PA), they are known as lethal toxin (LT) and edema toxin (ET). PA transports EF and LF into cells where they act as potent virulence factors and contribute to the pathogenesis of the disease.<sup>4</sup> The details of how LF and EF act to suppress the immune system, support dissemination of the bacteria, and contribute to the lethality of the disease is beginning to be revealed<sup>5</sup> and suggests that inhibiting the activity of these virulence factors could lead to an increase in survival of the infected host. Of the three forms of the disease, death due to inhalation anthrax is significantly higher when compared to fatalities resulting from cutaneous or gastrointestinal exposure, with fatality rates being >85% without supportive care.<sup>6</sup> While not contagious, the potential danger from this disease when used as an agent of bioterrorism was clearly demonstrated by the 2001 U.S. mail attacks, where fatality rates approaching 50% were




Figure 1. Current lead series of anthrax LFIs (**1–4**).

seen even after aggressive treatment with antibiotics.<sup>7</sup> Due to the relative ease of production and dispersal of anthrax spores, the potential for mass casualties due to *B. anthracis* release against an urban or military population is extremely high. As a result, new therapeutics are needed to supplement available methods of treatment and increase the survival rate of patients diagnosed with inhalation anthrax.

In part 2 of this series<sup>8</sup> we disclosed the identification of four core structures (Fig. 1) capable of providing anthrax LF inhibitors

\* Corresponding author.

E-mail address: [ajohnson@pantherabio.com](mailto:ajohnson@pantherabio.com) (A.T. Johnson).

† These authors contributed equally to this work.


(LFIs) with  $K_i$  values of less than 10 nM and in vivo efficacy in a rat LT model of anthrax. Below we present data from further studies directed towards evaluation of the current core structures, and structural modifications which have led to improved in vivo efficacy in the rat LT model.

In a previous report<sup>8</sup> we noted the necessity of having a benzylamine fragment located in the C2 side chain to achieve high intrinsic potency with this class of LFIs. We also showed that the replacement of this amine with an oxygen atom (NH to O) to give the corresponding benzyl ether either resulted in a >100-fold loss of intrinsic potency, and the all carbon chain analogs (NH to CH<sub>2</sub>) displayed a greater loss (>1000-fold) in potency. This led to the conclusion that a hydrogen bond or a significant electrostatic interaction was responsible for the observed increase in affinity of the benzylamine analogs to the LF protein. Since then, we have obtained a high resolution X-ray crystal structure of LFI **4** bound to the active site of LF (Fig. 2). Consistent with the LF-inhibitor structure obtained by the scientists at Merck<sup>9</sup>, the two oxygen atoms of hydroxamic acid group were found to chelate the catalytic zinc ion. The orientation and interatomic distances of this group relative to protein atoms is supportive of H-bonds between the NH-group and the backbone carbonyl oxygen of Gly657, the carbonyl oxygen with the hydroxyl group of Tyr728, and the hydroxamate hydroxyl with the catalytic Glu687 residue. This orientation of the hydroxamic acid group and the associated H-bonding network is essentially the same as seen first with hydroxamic acid (HA) based inhibitors thermolysin<sup>10</sup> and later with HA inhibitors bound to the matrix metalloproteinases (MMPs).<sup>11</sup> In contrast to our expectations based upon the Merck structure we found the C1–C4 axis of the 4-fluorophenyl ring present in the core structure of **4** to be at an angle of 57° relative to the axis of the 3-methyl-4-fluorophenyl ring of L915 when bound to LF. This results in a shift of loop residues Lys673, Gly674, and Val 675 away from the catalytic zinc-atom and creates a larger S1-prime subsite (see Fig. S1). Early modeling studies and the structure–activity relationships (SAR) for these compounds had predicted the core structure of the ligand to bind on the prime side of the catalytic site, however, we were not able to identify a single preferred binding mode for the C2-side chain on the non-prime side with any confidence. It is clear from


the present structure that the terminal phenyl ring points directly into the S3 pocket as opposed to the equally accessible S2 subsite<sup>12</sup> (see Fig. S2). Of particular interest was the presence of a bridging water molecule positioned to help stabilize the complex by H-bonding to both the benzyl amine nitrogen and Glu735. The clear electron density for the oxygen atom of this water molecule placed it 2.38 Å from the N-atom of the benzylamine and 2.58 Å from one of the carboxylate oxygen atoms of Glu735, the other of which is part of the first coordination sphere of the catalytic zinc atom. This H-bonding network combined with the SAR discussed earlier, provides strong support for this interaction as a key contributor to inhibitor potency.

While clearly important for high binding affinity towards the target, this benzylamine fragment also fits the classic pharmacophore model for CYP2D6 inhibitors<sup>14</sup> where the nitrogen is likely to be H-bonded to Glu216 or Asp301 in the CYP2D6 active site. Therefore, we sought a way to limit the potential for our LFIs to bind to this enzyme without sacrificing potency against LF. Since H-bonding is both distance and angle dependant, one potential way to disrupt this interaction is to introduce steric hindrance adjacent to the nitrogen atom. Of the two possible sites for introduction of a branch point on the C2 side chain, the  $\alpha$ -benzyl site appeared to be most suitable in terms of synthetic accessibility. It should be noted that at the time these changes in structure were being investigated, the X-ray crystal structure of **4** discussed above was not yet available. At the time, consideration of these structural modifications raised two questions with respect to the potential effect on inhibitor potency; how would the introduction of an R-group at this site, and the creation of a new stereogenic center, affect the intrinsic potency and the in vivo efficacy of this class of LFIs?


To answer these questions our first task was to identify an efficient synthetic route to stereochemically pure  $\alpha$ -substituted benzyl amines. Shown in Scheme 1 is the synthesis of the (*S*)-isobutyl-4-fluorobenzyl amine which is representative of the method used to prepare the needed  $\alpha$ -substituted benzylamines. Compound **5**, prepared by reaction of the lithium salt of (*S*)-isopropyl oxazolidinone with the acyl chloride derived from 4-fluorophenylacetic acid, was alkylated with methallyl bromide under standard conditions.<sup>15</sup> Catalytic hydrogenation using Pd-C provided **6** as a single diastereomer in good overall yield. Removal of the chiral auxiliary with lithium hydroperoxide to give carboxylic acid **7** was followed by a Curtius rearrangement<sup>16</sup> using an aqueous acid work up to afford the targeted  $\alpha$ -substituted benzylamine **8**. To



**Figure 2.** Representation<sup>13</sup> showing the crystallographic water bridging the amine of LFI **4** to Glu735 in the catalytic site of LF.



**Scheme 1.** Reagents and conditions: (a) (i) LiHMDS, THF, –78 °C, (ii) methallyl bromide, –78 °C to rt, (b) H<sub>2</sub>, Pd-C, EtOH, 3 h at rt, (c) LiOOH, THF/H<sub>2</sub>O, 0 °C, 1 h, (d) (i) ClCO<sub>2</sub>Et, Et<sub>3</sub>N, acetone, 0 °C, 15 min, (ii) NaN<sub>3</sub>, H<sub>2</sub>O, 0 °C, 30 min, (iii) toluene, reflux, 45 min, (iv) 8 N HCl, 0 °C to rt.

**Table 1**Anthrax LF inhibitory data for LFIs bearing  $\alpha$ -benzyl substituents on the C2-side chain

LFI	(*)	R	LF (FRET) ( $K_i$ nM)
<b>9</b>	R	Me	0.30
<b>10</b>	S	Me	0.49
<b>11</b>	R	Et	0.04
<b>12</b>	S	Et	0.11
<b>13</b>	R	iso-Butyl	0.23
<b>14</b>	S	iso-Butyl	1.30
<b>15</b>	R	–CH <sub>2</sub> Ph	0.60
<b>16</b>	S	–CH <sub>2</sub> Ph	2.00

Values are the average of two experiments; sd &lt;15%

investigate this modification in the C2-side chain, we selected the phenylpropionic acid core series (**2**) due to their ease of synthesis. These LFIs were then prepared following our previously published procedure involving reductive amination of the benzylamine reagent with the C2-side chain aldehyde connected to the phenylpropionic acid core.<sup>8</sup>

Inhibitory data for these LFIs against anthrax LF are provided in Table 1.<sup>12</sup> As a first observation, the size of the R-group can have a significant effect on the intrinsic potency of the LFI, with the most potent inhibitor bearing an ethyl group at the benzylic position. Given that this work was conducted prior to obtaining the X-ray structure of **4** bound to LF, we were somewhat surprised to see that introduction of a large substituent such as benzyl (**15**) can still afford sub-nanomolar inhibitors of LF. By examination of the crystal structure<sup>12</sup> of **4**, it can be easily seen how a large R-group attached to the  $\alpha$ -position can be accommodated without disrupting the


interactions essential for high affinity binding (see Fig. S3). A second finding was that with the exception of R = methyl, the (R)-isomers were more potent by three to fivefold relative to analogs of the (S)-configuration. When considering both of these parameters, a change in potency of 50-fold can be observed (cf. **11** vs **16**). Perhaps most important, it should be possible to modify the drug-like properties of a given LFI by introduction of various R-groups to this site with minimal concern for size or absolute stereochemistry.

Having identified structural features which provided sub-nanomolar LFIs in four core structures, we set out to see if one or more of these structural classes would be preferred for the lead optimization phase of this work. Towards this end we chose to compare in vitro potency, toxicity, physicochemical (PC) properties, and in vivo efficacy of matched pairs of LFIs representing each core structure bearing an unsubstituted or  $\alpha$ -substituted benzylamine on the C2-side chain. Based on the results presented in Table 1, and to ease the burden of synthesis, we selected the racemic  $\alpha$ -ethylbenzylamine analogs for our comparison of C2-side chain effects. The data collected from these studies is provided in Tables 2 and 3 below.

The in vitro potency, potential for toxicity, PC properties, and the activity of these compounds versus possible anti-targets (MMPs, CYP2D6, and hERG) is provided in Table 2. In terms of intrinsic potency, the analogs based upon the phenoxyacetic acid core structure are the least potent, though they still possess  $K_i$  values <2 nM. Cytotoxicity is very low for all of the analogs with the observed CC<sub>50</sub> values being 20K-fold greater than their respective  $K_i$  values. The PC properties for all of the core structures are very similar. Molecular mass is well below 500 Da for each series and differs by <50 mass units. ClogP values are on the high side of the preferred range with all being >3.0 but still less than 5.0 while the calculated polar surface areas are at the lower end of the preferred range of 75 Å<sup>2</sup> < PSA < 125 Å<sup>2</sup>. Determination of relative permeability using a hexadecane based PAMPA assay<sup>17</sup> show all of the LFIs to have fair to good permeability with logP<sub>e</sub> values being >–6.0. While no apparent trend emerges with respect to the

**Table 2**

The in vitro potency, potential for toxicity, and PC properties for match pairs of LFIs representing each of the four core structures




LFI	MW	$K_i^a$ (nM)	CC <sub>50</sub> <sup>a</sup> ( $\mu$ M)	ClogP <sup>b</sup>	PSA <sup>c</sup> (Å <sup>2</sup> )	PAMPA <sup>d</sup> (logP <sub>e</sub> )	MMP $K_i$ ( $\mu$ M) <sup>a</sup>					CYP2D6 <sup>a</sup> ( $\mu$ M)	hERG <sup>a</sup> ( $\mu$ M)
							–1	–3	–9	–12	–14		
<b>1</b>	391.2	0.24	61	3.7	92.6	–5.9	>50	>50	>50	>50	>50	1.35	1.23
<b>17</b>	419.2	0.17	32	4.6	88.1	–5.1	>50	>50	>50	>50	>50	0.24	0.95
<b>2</b>	390.2	0.13	16	4.0	88.9	–4.8	>50	>50	>50	>50	>50	0.02	4.65
<b>18</b>	418.2	0.31	15	4.8	74.6	–4.1	>50	>50	>50	>50	>50	0.08	13.3
<b>3</b>	392.2	1.20	26	3.8	86.9	–5.2	>50	>50	>50	>50	>50	0.23	0.79
<b>19</b>	420.2	1.00	21	4.7	83.9	–4.4	>50	>50	>50	>50	>50	0.34	2.7
<b>4</b>	406.2	0.58	55	3.2	81.9	–5.8	33	>50	21	2.3	>50	1.26	2.0
<b>20</b>	434.3	0.27	35	4.0	80.1	–5.1	47	31	11	12	>50	0.16	10.0

<sup>a</sup> See Supplementary data for experimental procedures; IC<sub>50</sub> values given for CYP2D6 and hERG.<sup>b</sup> ClogP calculated with ChemDraw v12.0.<sup>c</sup> PSA calculated using PCModel v. 8.5.<sup>d</sup> PAMPA determined by the method of Wohnsland<sup>17</sup> using Millipore multiscreen 96-well plates

**Table 3**

The in vitro ADME and rat LT challenge assay data for match pairs of LFI's representing each of the four core structures



LFI	$K_i^a$ (nM)	$\text{CC}_{50}^a$ ( $\mu\text{M}$ )	$\text{ClogP}^b$	$\text{ElogD}^c$	In vitro ADME <sup>d</sup>			5.0 mg/kg <sup>e</sup>		2.5 mg/kg <sup>e</sup>		1.25 mg/kg <sup>e</sup>	
					M	P	U	surv	rMST	surv	rMST	surv	rMST
<b>1</b>	0.24	61	3.7	2.3	60	90	38	3/3	—	3/5	16.8	nt	—
<b>17</b>	0.17	32	4.6	3.3	75	84	74	3/3	—	3/3	—	0/3	2.4
<b>2</b>	0.13	16	4.0	2.2	18	100	79	3/3	—	1/3	19.3	nt	—
<b>18</b>	0.31	15	4.8	2.9	55	95	100	3/3	—	3/3	—	5/6	4.2
<b>3</b>	1.20	26	3.8	3.1	3	61	76	0/3	16.0	nt	—	nt	—
<b>19</b>	1.00	21	4.7	3.3	7	38	75	1/3	16.0	nt	—	nt	—
<b>4</b>	0.58	55	3.2	2.4	91	98	99	2/3	16.0	nt	—	nt	—
<b>20</b>	0.27	35	4.0	2.9	75	94	100	3/3	—	2/5	16.8	nt	—

<sup>a</sup> See Supplementary data for experimental procedure.<sup>b</sup>  $\text{ClogP}$  calculated with ChemDraw v12.0.<sup>c</sup>  $\text{ElogD}$  measure using the method of Lombardo.<sup>15</sup><sup>d</sup> Values given indicate percent of compound remaining at  $t = 30$  min for M = microsomal stability, U = UGT assays and the percent remaining at 3 h for P = plasma stability.<sup>e</sup> Fischer 344 rats were dosed IV with LFI's followed 20–30 min later by 10  $\mu\text{g}$  of LT (10  $\mu\text{g}$  of PA + 10  $\mu\text{g}$  of LF); surv. = Number of survivors per group. rMST = MST(LFI)/MST(controls) where vehicle treated controls (MST =  $74.8 \pm 7.2$  min ( $n = 11$ ); when less than 50% deaths occurred the average survival time was used; rMST = aveST(LFI)/MST(controls); nt = not tested, (—) = not applicable. Survival curves for all LFI's at each dose showed statistical significance ( $P < 0.05$ ) relative to controls.**Table 4**PK data for LFI **20** after single dose of 10 mg/kg (SC; DMSO:PEG400:pH6 citrate buffer, 2:10:88) in NZW rabbits.

$K_i$	0.27 nM
Dose (SC)	10 mg/kg
$T_{\text{max}}$	0.3 h
$C_{\text{max}}$	561.3 ng/mL (1.3 $\mu\text{M}$ )
$t_{1/2}(\beta)$	5.3 h
$\text{AUC}_{\infty}$	2637.6 ng h/mL
$[\text{20}]_{12 \text{ h}}$	79 nM

specific core structures, better permeability is seen with the  $\alpha$ -ethyl analogs **17** to **20**. Selectivity for LF versus various MMPs was excellent, being >50K-fold for the one atom linking group series ( $X = \text{NH}$ ,  $\text{CH}_2$ ,  $\text{O}$ ) and >4000-fold for the  $\gamma$ -ether series represented by LFI **4** and **20**. Consistent with the current pharmacophore models for binding to CYP2D6, many of these compounds were found to be strong inhibitors of this enzyme. Further, when comparing analogs where  $R = \text{H}$  versus  $R = \text{ethyl}$ , introduction of steric hindrance by a simple alkyl group at the benzylic position did not decrease CYP2D6 inhibitory activity. Activity against hERG was considerably lower compared to CYP2D6, but still significant (<10  $\mu\text{M}$ ) for all but two analogs. Taken together, these data did not show a bias towards any one core structure in terms their suitability for the lead optimization process, however, the potential for each series to significantly inhibit CYP2D6 and hERG was made clear.

Continuing our investigation of the four core structures, the same set of eight LFI's were tested in various in vitro ADME assays and finally in the rat LT challenge assay.<sup>18</sup> A concurrent goal of these studies was to determine if the data obtained from the in vitro ADME assays would correlate with survival outcomes ob-

served in the rat LT challenge experiments and aid in selection of future candidates for in vivo studies. The results of this work are provided in Table 3. We also determined the  $\text{ElogD}$  values for these compounds which show good correlation with  $\log D_{7.4}$  values when applied to neutral or basic compounds.<sup>19</sup> In this case, the data shows these LFI's to have the potential for better drug-like properties at physiologic pH when compared to evaluation of the  $\text{ClogP}$  values alone.

As in our previously studies, the rat LT challenge study was conducted by dosing Fischer 344 rats (IV) with the LFI followed 20–30 min later by a 10  $\mu\text{g}$  dose (IV) of LT (10  $\mu\text{g}$  PA + 10  $\mu\text{g}$  LF). When administered at a dose of 5.0 mg/kg (Table 3), five of the eight LFI's provided 100% protection, one animal was lost in the group treated with LFI **4**, but only a single animal survived from the two groups treated with the LFI's based on the phenoxy acetic acid core structure (**3** and **19**). This finding was qualitatively consistent with the observed in vitro ADME data where **3** and **19** displayed the lowest stability in the microsomal and plasma stability assays among all of the compounds tested. Of particular significance was the low metabolic stability for these compounds in the rat liver microsomal assay where <10% of either compound remained after incubation for 30 min. This observation combined with the fact that the animals were challenged with lethal toxin 20–30 min after receiving the LFI is consistent with the inability of **3** and **19** to provide significant protection from the lethal effects of LF in this experiment. In an attempt to probe further into possible differences in efficacy due to the core structure, the LFI's which provided full protection at 5.0 mg/kg were then tested at 2.5 mg/kg. In this case, two of the five compounds tested (**17** and **18**) were still able to protect all of the animals in their respective groups. The finding that the LFI's which perform best were  $\alpha$ -substituted benzylamine analogs, combined with a similar trend seen with the  $\gamma$ -ether analogs **4**



(R = H) and **20** (R = Et), indicates that  $\alpha$ -substitution appears to benefit survival in this model of anthrax LT intoxication. In a final experiment LFI **17** and **18** were tested at 1.25 mg/kg. At this dose, neither LFI was able to fully protect the animals from death due to LF, however, the phenylpropionic acid derivative **18** appeared to be more effective (5/6 survivors) compared to the aniline based analog **17** (0/3 survivors).

The pathogenesis of inhalation anthrax observed in the rabbit is considered to be a good representation of the disease course in humans.<sup>20</sup> In preparation for these studies we determined the PK profile of LFI **20** in NZW rabbits. Since the current protocol call for the administration of the drug over several days, and may require multiple doses of the test compound per day, we selected the subcutaneous (SC) route of administration for this initial study. The PK data for LFI **20** shown in Table 4 indicates that this compound is rapidly absorbed when dosed at 10 mg/kg via the SC route and results in a good peak plasma concentration ( $C_{\max}$  = 1.3  $\mu$ M). In addition, the terminal half-life ( $t_{1/2\beta}$ ) and AUC values suggest a good residence time for this compound. Finally, the mean plasma concentration of **20** at the 12 h time point indicates that the compound is present at levels more than 290-fold above the  $K_i$  value which would support a twice a day dosing schedule in a future efficacy study.

In summary, evaluation of four core structures capable of providing sub-nanomolar inhibitors of anthrax lethal factor was accomplished by comparing the potential for toxicity, PC properties, in vitro ADME profiles, and relative efficacy in a rat LT model of LF intoxication. Based upon these results, the phenoxyacetic acid core structure appears to be inferior to the other three tested. All of the core structures provided analogs which had significant inhibitory activity against CYP2D6 and hERG indicating that new analogs should be tested against these anti-targets as part of the lead candidate selection process. Addition of an R-group at the benzylic position of the C2-side chain was well tolerated with respect to intrinsic potency, was consistent with the X-ray structure of LFI **4** bound to the catalytic site of LF, but did not decrease inhibitor potency against CYP2D6. In addition, this modification appeared to provide analogs with improved protection profiles in the rat LT challenge model. Compound **20** was also found to have a good PK profile when administered SC to NZW rabbits and supports the potential of these inhibitors to provide protection in a rabbit spore challenge model of inhalation anthrax.

## Acknowledgments

We thank the National Institutes of Health for their support of this work with Grants R44 AI052587 and U01 AI078067. The rat

LT challenge studies were supported by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases. The PK study was conducted by Covance Laboratories, Inc. (Madison, WI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID or the NIH.

## Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.bmcl.2012.01.095.

## References and notes

- Tournier, J.-N.; Paccani, S. R.; Quesnel-Hellmann, A.; Baldari, C. T. *Mol. Aspects Med.* **2009**, *30*, 456.
- (a) Duesbury, N. S.; Webb, C. P.; Leppla, S. H.; Gordon, V. M.; Copeland, T. D.; Ahn, N. G.; Oskarsson, M. K.; Fukasawa, K.; Paull, K. D.; Vande Woude, G. F. *Science* **1998**, *280*, 734; (b) Vitale, G.; Bernardi, L.; Napolitani, G.; Mock, M.; Montecucco, C. *Biochem. J.* **2000**, *352*, 739.
- (a) Leppla, S. H. *Proc. Natl. Acad. Sci. U.S.A.* **1982**, *79*, 3162; (b) Tang, W.-J.; Guo, Q. *Mol. Aspects Med.* **2009**, *30*, 423.
- Collier, R. J.; Young, J. A. *Annu. Rev. Cell Dev. Bio.* **2003**, *19*, 45.
- Moayeri, M.; Leppla, S. H. *Mol. Aspects Med.* **2009**, *30*, 439.
- Holty, J.-E. C.; Bravata, D. M.; Liu, H.; Olshen, R. A.; McDonald, K. M.; Owens, D. K. *Ann. Intern. Med.* **2006**, *144*, 270.
- Jernigan, J. A.; Stephens, D. S.; Ashford, D. A.; Omenaca, C.; Topiel, M. S.; Galbraith, M., et al. *Emerg. Infect. Dis.* **2001**, *7*, 933.
- Kim, S.; Jiao, G.-S.; Moayeri, M.; Crown, D.; Cregar-Hernandez, L.; McKasson, L.; Margosiak, S. S.; Leppla, S. H.; Johnson, A. T. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2030.
- Shoop, W. L.; Xiong, Y.; Wiltsie, J.; Woods, A., et al. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 7958.
- Holmes, M. A.; Matthews, B. W. *Biochemistry* **1981**, *20*, 6912.
- Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. *Curr. Med. Chem.* **2001**, *8*, 425.
- See Supplementary data for details on experimental procedures and additional figures from the crystallographic study.
- This image was made with VMD which was developed with NIH support by the Theoretical and Computational Biophysics group at the Beckman Institute, University of Illinois at Urbana-Champaign. <http://www.ks.uiuc.edu/Research/vmd/>.
- Smith, D. A.; van de Waterbeemd, H.; Walker, D. K. In *Methods and Principles in medicinal Chemistry*; Mannhold, R., Kubinyi, H., Timmerman, H., Eds.; Wiley-VCH Verlag GmbH: Weinheim, 2001; Vol. 13, pp 78–80.
- Evans, D. A.; Ennis, M. D.; Mathre, D. J. *J. Am. Chem. Soc.* **1982**, *104*, 1737.
- Kaiser, C.; Weinstock, J. *Org. Synth.* **1971**, *51*, 48.
- Wohnsland, F.; Faller, B. *J. Med. Chem.* **2001**, *44*, 923.
- Gupta, P.K.; Moayeri, M.; Crown, D.; Fattah, R.J.; Leppla, S.H., *PLoS One* **2008**, *3*, e3130. Note: this assay was not designed to model inhalation anthrax in humans but to demonstrate that a small molecule LFI can prevent death due to anthrax lethal factor in an in vivo model. The protocol used provides for a reproducible assay with the resolution necessary to rank order the in vivo efficacy of LFIs in an animal model where death results specifically from the action of anthrax LF.
- Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. *J. Med. Chem.* **2001**, *44*, 2490.
- Goossens, P. L. *Mol. Aspects Med.* **2009**, *30*, 467.